1.14

9.62% +0.10

Cingulate Inc (CING)

Overview News Price History Financials Discussions Forecast

Cingulate Inc stock is currently priced at $1.14, with a 24-hour trading volume of 203.76K. It has seen a +9.62% increased in the last 24 hours and a +6.54% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.01 pivot point. If it approaches the $1.15 resistance level, significant changes may occur.

Previous Close:

$1.04

Open:

$1.02

24h Volume:

203.76K

Market Cap:

$6.77M

Revenue:

Net Income/Loss:

$-21.21M

P/E Ratio:

-0.6746

EPS:

-1.69

Net Cash Flow:

$-16.86M

1W Performance:

+35.71%

1M Performance:

+6.54%

6M Performance:

-86.26%

1Y Performance:

-94.84%

1D Range:

$1.01

$1.16

52W Range:

$0.75

$23.40

Cingulate Inc Stock (CING) Company Profile

Name

Cingulate Inc

Sector

Healthcare (1193)

Industry

Biotechnology (685)

Phone

913 942 2300

Address

1901 West 47th Place, Kansas City

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CING's Discussions on Twitter

Cingulate Inc Stock (CING) Latest News

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

GlobeNewswire Inc.

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

GlobeNewswire Inc.

Cingulate Announces Closing of $7.5 Million Public Offering

GlobeNewswire Inc.

Cingulate Inc Stock (CING) Financials Data

Cingulate Inc (CING) Net Income 2024

CING net income (TTM) was -$21.21 million for the quarter ending September 30, 2023, a -34.85% decrease year-over-year.

Cingulate Inc (CING) Cash Flow 2024

CING recorded a free cash flow (TTM) of -$16.86 million for the quarter ending September 30, 2023, a +0.94% increase year-over-year.

Cingulate Inc (CING) Earnings per Share 2024

CING earnings per share (TTM) was -$32.60 for the quarter ending September 30, 2023, a -10.14% decline year-over-year.

Cingulate Inc Stock (CING) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Callahan Jennifer L.	Corporate Controller	Sep 15 '23	Buy	0.67	5,000	3,348	45,508
Werth Peter J.	Director	Aug 11 '23	Buy	0.55	1,823,155	1,000,001	2,798,320
Callahan Jennifer L.	Corporate Controller	May 15 '23	Buy	1.01	2,000	2,020	40,508
Callahan Jennifer L.	Corporate Controller	May 12 '23	Buy	1.08	4,000	4,320	38,508

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.